Current Aspects of Paraoxonase-1 Research

The HDL Handbook: Biological Functions and Clinical Implications: Second Edition

Volumn , Issue , 2014, Pages 273-291

  Mackness, Mike ^a   Mackness, Bharti ^a  

^a Miami Playa   (Spain)

Author keywords

Aging; Atherosclerosis; HDL; Inflammation; LDL; Oxidation; Paraoxonase 1; Paraoxonases; Quorum quenching; Toxicology

Indexed keywords

EID: 84930378231     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-407867-3.00011-1     Document Type: Chapter

References (109)

1. Rajkovic M.G., Rumora L., Barisic K. The paraoxonase 1, 2 and 3 in humans. Biochemia Medica 2011, 21:122-130.
2. Mackness B., Durrington P.N., Mackness M.I. Human serum paraoxonase. Gen Pharmac 1998, 31:329-336.
3. Mazur A. An enzyme in the animal organism capable of hydrolysing the phosphorus-fluorine bond of alkyl fluorophosphates. J Biol Chem 1946, 164:271-289.
4. Aldridge W.N. Serum esterases 2. An enzyme hydrolysing diethyl p-nitrophenylphosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J 1953, 53:117-124.
5. Davidson W.S., Silva R.A.G.D., Chantepie S., Lagor W.R., Chapman M.J., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters-Relevance to antioxidative function. Arteriioscler Thromb Vasc Biol 2009, 29:870-876.
6. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Maged R., et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004, 11:412-419.
7. Primo-Parma S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-509.
8. Rodriguez-Sanabria F., Rull A., Beltran-Debon R., Aragones G., Camps J., Mackness B., et al. Tissue distribution and expression of paraoxonases and chemokines in the mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. J Mol Histol 2010, 41:379-386.
9. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004, 37:1304-1316.
10. Reddy S.T., Devarajan A., Bourquard N., Shih D., Fogelman A.M. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?. Curr Opin Lipidol 2008, 19:405-408.
11. Deakin S.P., James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004, 107:435-447.
12. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase activity. Biochem Pharmacol 2005, 69:541-550.
13. Schrader C., Rimbach G. Determinants of paraoxonase 1 status: genes, drugs and nutrition. Curr Med Chem 2011, 18. 5624-5623.
14. Leviev I., Negro F., James R.W. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997, 17:2935-2939.
15. Leviev I., James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000, 20:516-521.
16. Kim D.S., Burt A.A., Ranchalis J.E., Richter R.J., Marshall J.K., Eintracht J.F., et al. Additional common polymorphisms in the PON gene cluster predict PON1 activity but not vascular disease. J Lipids 2012, 2012:476316.
17. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R. Arterioscl Thromb Vasc Biol 1998, 10:1617-1624.
18. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letts 1998, 423:57-60.
19. Wheeler J.G., Keavney B.D., Watkins H., Collins R., Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004, 363:689-695.
20. Durrington P.N. Hyperlipidaemia. Diagnosis and management 1995, Butterworth Heinemann, London. 2nd ed.
21. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl. J Med 1989, 320:915-924.
22. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
23. Chisholm G.M., Penn M.S. Oxidised lipoproteins and atherosclerosis. Atherosclerosis and coronary artery disease 1996, 129-149. Lippincott-Raven, Philadelphia. V. Fuster, R. Ross, E.J. Topol (Eds.).
24. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., Protter A.A. CD36 is a receptor for oxidised low density lipoprotein. J Biol Chem 1993, 268:11811-11816.
25. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
26. Shah P.K. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr Opin Cardiol 2010, 25:603-608.
27. Fisher E.A., Feig J.E., Hewing B., Hazen S.L., Smith J.D. High-density lipoprotein function, dysfunction and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012, 32:2813-2820.
28. Mackness M.I., Abbott C.A., Arrol S., Durrington P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993, 294:829-835.
29. Mackness M.I., Durrington P.N. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995, 115:243-253.
30. Mackness B., Mackness M. The antioxidant properties of high-density lipoproteins in atherosclerosis. Panminerva Med 2012, 54:83-90.
31. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letts 1991, 286:152-154.
32. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
33. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Fault K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase-inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 1995, 96:2882-2891.
34. Ahmed Z., Ravandi A., Maguire G.F., Emili A., Draganov D., La Du B.N., et al. Apolipoprotein AI promotes the formation of phosphatidylcholine core aldehydes that are hydrolysed by paraoxonase (PON1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 2001, 276:24473-24481.
35. Draganov D.I., La Du B.N. Pharmacogenetics of paraoxonase: a brief review. Naunyn-Schmiedeberg's Arch Pharmacol 2004, 369:78-88.
36. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998, 101:1581-1590.
37. Deakin S.P., Bioletto S., Bochaton-Piallat M.L., James R.W. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med 2011, 50:102-109.
38. Berrougui H., Loued S., Khalil A. Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages. Free Rad Biol Med 2012, 52:1372-1381.
39. Tavori H., Aviram M., Khatib S., Musa R., Mannheim D., Karmeli R., et al. Paraoxonase 1 protects macrophages from atherogenicity of a specific triglyceride isolated from human carotid lesion. Free Rad Biol Med 2011, 51:234-242.
40. Navab M., Imes S.S., Hama S.Y., Hough G.P., Ross L.A., Bork R.W., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88:2039-2046.
41. Mackness B., Hine D., Liu Y., Mastorikou M., Mackness M. Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. BBRC 2004, 318:680-683.
42. Younis N.N., Soran H., Charlton-Menys V., Sharma R., Hama S., Pemberton P., et al. High-density lipoprotein impedes glycation of low-density lipoprotein. Diabet Vasc Dis Res 2013, 10:152-160.
43. Rozenberg O., Shih D.M., Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005, 181:9-18.
44. Mackness B., Quarck R., Verreth W., Mackness M., Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:1545-1550.
45. Guns P.-J., Van Assche T., Verreth W., Fransen P., Mackness B. Mackness, M, Holvoet P, Bull H. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br J Pharmacol 2008, 153:508-516.
46. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
47. Shih D.M., Gu L., Xia Y.-R., Navab M., Li W.-F., Hama S., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
48. Mackness B., Hunt R., Durrington P.N., Mackness M.I. Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:1233-1238.
49. Marsillach J., Camps J., Beltran-Debon R., Rull A., Aragones G., Maestre-Martinez C., et al. Immunohistochemical analysis of paraoxonases 1 and 3 in human atheromatous plaques. Eur J Clin Invest 2011, 41:308-314.
50. Rozenberg O., Shiner M., Aviram M., Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Rad Biol Med 2008, 44:1951-1959.
51. Koren-Gluzer M., Aviram M., Meilin E., Hayek T. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release. Atherosclerosis 2011, 219:532-537.
52. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107:2775-2779.
53. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
54. van Himbergen T.M., van der Schouw Y.T., Voorbij H.A.M., van Tits L.J.H., Stalenhoef A.F.H., Peeters P.H.M., et al. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 2008, 198:408-414.
55. Ikeda Y., Inoue M., Suehiro T., Arii K., Kumon Y., Hashimoto K. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol 2009, 46:239-242.
56. Troughton J.A., Woodside J.V., Yarnell J.W.G., Arveiler D., Amouyel P., Ferrieres J., et al. Paraoxonase activity and coronary heart disease in healthy middle-aged males: the PRIME study. Atherosclerosis 2008, 197:556-563.
57. Birjmohun R.S., Vergeer M., Stroes E.S., Sandhu M.S., Ricketts S.L., Tanck M.W., et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC- Norfolk prospective population study. PLoS One 2009, 4:e6809.
58. Wang M., Lang X., Cui S., Zou L., Wang S., Wu X. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease. DNA Cell Biol 2012, 31:975-982.
59. Ikeda Y., Suehiro T., Itahara T., Inui Y., Chikazawa H., Inoue M., et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 2007, 67:358-365.
60. Mackness B., Davies G.K., Turkie W., Lee E., Roberts D.H., Hill E., et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 2001, 21:1451-1457.
61. Tang W.H.W., Hartiala J., Fan Y., Wu Y., Stewart A.F.R., Erdmann J., et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012, 32:2803-2812.
62. 55 genotype. Arterioscl Thromb Vasc Biol 2000, 20:2441-2447.
63. Jakubowski H. Protein homocysteinylation: possible mechanisms underlying pathological consequences of elevated homocysteine levels. FASEB J 1999, 13:2277-2283.
64. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000, 130:377S-381S.
65. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase-a protective mechanism against protein s-homocysteinylation. J Biol Chem 2000, 275:3957-3962.
66. Hine D., Mackness B., Mackness M. Co-incubation of PON1, APO A1 and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life 2012, 64:157-161.
67. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D.M., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011, 121:2693-2708.
68. Liu M.-L., Scalia R., Mehta J.L., Williams K.J. Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns. Arterioscler Thromb Vasc Biol 2012, 32:2113-2121.
69. Navab M., Hama-Levy S., Van Lenten B.J., Fonarow G.C., Carelinez C.J., Castellani L.W., et al. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997, 99:2005-2019.
70. Goswami B., Tayal D., Gupta N., Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 2009, 410:1-12.
71. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fogelman A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2006, 2:504-511.
72. Costa L.G., Giordano G., Cole T.B., Marsillach J., Furlong C.E. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology 2013, 307:115-122.
73. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomics of the paraoxonase (PON1) polymorphisms: effect on pesticide sensitivity, cardiovascular disease and drug metabolism. Ann Rev Med 2003, 54:371-392.
74. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., et al. Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 2000, 10:767-779.
75. Haley R.W., Billecke S., La Du B.N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 2000, 157:227-233.
76. Hotopf M., Mackness M.I., Nikolau V., Collier D.A., Curtis C., David A., et al. Paraoxonase in Persian Gulf War veterans. J Occup Environ Med 2003, 45:668-675.
77. Mackenzie Ross S.J., Brewin C.R., Curran H.V., Furlong C.E., Abraham-Smith K.M., Harrison V. Neuropsychological and psychiatric functioning in sheep farmers exposed to low levels of organophosphate pesticides. Neurotoxicol Teratol 2010, 32:452-459.
78. Cherry N., Mackness M., Mackness B., Dippnall M., Povey A. "Dippers' flu" and its relationship to PON1 polymorphisms. Occ Environm Med 2011, 68:211-217.
79. Mackness B., Durrington P., Povey A., Thomson S., Dippnall M., Mackness M., et al. Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 2003, 13:81-88.
80. da Silva J., Moraes C.R., Heuser V.D., Andrade V.M., Silva F.R., Kvitko K., et al. Evaluation of genetic damage in a Brazilian population occupationally exposed to pesticides and its correlation with polymorphisms in metabolising genes. Mutagenesis 2008, 23:415-422.
81. Lee B.W., London L., Poulauskis J., Myers J., Christiani D.C. Association between human paraoxonase gene polymorphism and chronic symptoms in pesticide-exposed workers. J Occup Environ Med 2003, 45:118-122.
82. Lacasana M., Lopez-Flores I., Rodriguez-Barranco M., Aguilar-Garduno C., Blanco-Munoz J., Perez-Mendez O., et al. Interaction between organophosphate pesticide exposure and PON1 activity on thyroid function. Toxicol Appl Pharmacol 2010, 249:16-24.
83. Manthripragada A.D., Costello S., Cokburn M.G., Bronstein J.M., Ritz B. Paraoxonase 1, agricultural organophosphate exposure and Parkinson disease. Epidemiology 2010, 21:87-94.
84. Searles Nielsen S., Mueller B.A., DeRoos A.J., Viernes H.M., Farin F.M., Checkoway H. Risk of brain tumors in children and susceptibility to organophosphorus insecticide; the potential role of paraoxonase (PON1). Environ Health Perspect 2005, 113:909-913.
85. Berkowitz G.S., Wetmur J.G., Birman-Deych E., Obel J., Lapinski R.H., Godbold J.H., et al. In utero pesticide exposure, maternal paraoxonase activity and head circumference. Environ Health Perspect 2004, 112:388-391.
86. Harley K.G., Huen K., Schall R.A., Holland N.T., Bradman A., Barr D.B., et al. Association of organophosphate pesticide exposure and paraoxonase with birth outcome in Mexican American Women. PLoS One 2011, 6:e23923.
87. Engel S.M., Wetmur J., Chen J., Zhu C., Barr D.B., Canfield R.L., et al. Prenatal exposure to organophosphates, paraoxonase 1 and cognitive development in childhood. Environ Health Perspect 2011, 119:1182-1188.
88. Eskenazi B., Huen K., Marks A., Harley K.G., Bradman A., Barr D.B., et al. PON1 and neurodevelopment in children from the CHAMACOS study exposed to organophosphate pesticides in utero. Environ Health Perspect 2010, 118:1775-1781.
89. Garliardi S., Abel K., Bianchi M., Milani P., Bernuzzi S., Corato M., et al. Regulation of FMO and PON detoxication systems in ALS human tissues. Neurotox Res 2013, 23:370-377.
90. Ricci C., Battistini S., Cozzi L. Lack of association of PON polymorphisms with sporadic ALS in an Italian population. Neurobiol Aging 2011, 32:552. e7-552.e13.
91. Slowik A., Tomik B., Wolkow P.P., Partyka D., Turaj W., Malecki M.T., et al. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 2006, 67:766-770.
92. Ticozzi N., LeClerc A.L., Keagle P.J., Glass J.D., Wills A.M., van Blitterswijk M., et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol 2010, 68:102-107.
93. Wills A.M., Landers J.E., Zhang H., Richter R.J., Caraganis A.J., Cudkowicz M.E., et al. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology 2008, 70:929-934.
94. Saadat M. Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Epidemiol 2012, 36:e101-e103.
95. Bobin-Dubigeon C., Jaffre I., Joalland M.-P., Classe J.-M., Campone M., Herve M., et al. Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence. Clin Biochem 2012, 45:1503-1505.
96. Camps J., Pujol I., Ballester F., Joven J., Simo J.M. Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in gram-negative bacteria. Antimocrob Agents Chemother 2011, 55:1325-1331.
97. Simanski M., Babucke S., Eberl L., Harder J. Paraoxonase 2 acts as a quorum-quenching factor in human keratinocytes. J Invest Dermatol 2012, 132:2296-2299.
98. Teiber J.F., Horke S., Haines D.C., Chowdhary P.K., Xiao J., Kramer J.K., et al. Dominant role of paraoxonases in inactivation of the pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone. Infect Immun 2008, 76:2512-2519.
99. Ozer E.A., Pezzulo A., Shih D.M., Chun C., Furlong C., Lusis A.J., et al. Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol Lett 2005, 253:29-37.
100. Stoltz D.A., Ozer E.A., Taft P.J., Barry M., Liu L., Kiss P.J., et al. Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J Clin Invest 2008, 118:3123-3131.
101. Pezzulo A.A., Hornick E.E., Rector M.V., Estin M., Reisetter A.C., Taft P.J., et al. Expression of human paraoxonase 1 decreases superoxide levels and alters bacterial colonisation in the gut of Drosophila melanogaster. PLoS One 2012, 7:e43777.
102. Seres I., Paragh G., Deschene E., Fulop T., Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004, 39:59-66.
103. Jaouad L., de Guise C., Berrougui H., Cloutier M., Isabelle M., Fulop T., et al. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis 2006, 185:191-200.
104. Lescai F., Marchegiani F., Franceschi C. PON1 is a longevity gene: results of a meta-analysis. Ageing Res Rev 2009, 8:277-284.
105. Lee Y.S., Park C.O., Noh J.Y., Jin S., Lee N.R., Noh S., et al. Knockdown of paraoxonase 1 expression influences ageing of human dermal microvascular endothelial cells. Exp Dermatol 2012, 21:682-687.
106. Christison J.K., Rye K.A., Stocker R. Exchange of oxidised cholesteryl-linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995, 36:2017-2026.
107. Klimov A.N., Nikiforova A.A., Kuzmin A.A., Kuznetsov A.S., Mackness M.I. Is high density lipoprotein a scavenger for oxidised phospholipids of low density lipoprotein? Advances in Lipoprotein and Atherosclerosis Research. Diagnostics and Treatment 1998, Gustav Fischer Verlag, Jena, 78-82.
108. Camps J., Marsillach J., Joven J. Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. Mini Rev Med Chem 2009, 9:911-920.
109. Costa L.G., Giordano G., Furlong C.E. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011, 81:337-344.